Focus. Together. For patients and society.
Partnering for success
Ipsen Way of Being
Guided by patient outcomes
WHO WE ARE
As a mid-sized global biopharmaceutical company, Ipsen improves patients’ lives through research, innovation and the development of transformative medicines in Oncology, Rare Disease and Neuroscience.
WHAT WE DO
Improving people’s lives and health outcomes by focusing on areas of high unmet medical need, we are accelerating our momentum and rapidly boosting our pipeline to bring the full potential of our innovative medicines to patients.
Learn more
Our strategy has been instrumental in making us a leader in our field. Our global presence, resources, expertise and strong track record commercializing our medicines are resulting in a real impact for people living with high unmet medical needs. We’re leveraging the full force of Ipsen’s infrastructure, innovation and passion to develop new therapies and valuable collaborations.
Ipsen Canada is a Great Place to Work®
Best Workplaces in Health Care 2024
Great Place To Work Certified 2023-2024
Best Workplaces in Health Care 2023
Great Place To Work Certified 2022-2023
Best Workplaces for Inclusion 2022
How Ipsen helps
Ipsen focuses on three key therapeutic areas, leveraging all our resources to help patients with unmet medical needs.
Oncology
With over 35 years of oncology experience, our growing portfolio is focused on difficult-to-treat cancers including those with neuroendocrine tumors, advanced kidney cancer, liver cancer and advanced or metastatic, differentiated thyroid cancer.
Rare Diseases
We continue to evolve and grow our research efforts in the area of rare and ultra-rare diseases with focus on pituitary pathologies, growth disorders, and ultra-rare bone diseases, including fibrodysplasia ossificans progressiva (FOP).
Neuroscience
Ipsen brings 30 years of clinical experience to advancing the understanding of neurological conditions such as spasticity and cervical dystonia. We are a global leader in the research, development, manufacturing, and commercialization of neurotoxins.
